2023 ELCC | MULTIPLE STUDIES OF HANSOH PHARMA'S AUMOLERTINIB TO BE PRESENTED ONCE MORE AT AUTHORITATIVE INTERNATIONAL ACADEMIC CONFERENCE

HANSOH PHARMA'S AMEILE BECOMES AVAILABLE AS A REIMBURSABLE DRUG FOR FIRST-LINE TREATMENT, FULLY ENHANCING THE ACCESSIBILITY OF MEDICATION

AUTHORITATIVE ENDORSEMENT: HANSOH PHARMA'S HENGMU IS RECOMMENDED FOR FIRST-LINE TREATMENT IN THE CHINESE EXPERT CONSENSUS ON ANTIVIRAL THERAPY FOR HBV RELATED HEPATOCELLULAR CARCINOMA (2023 EDITION)

FIRST PATIENT DOSING OF XINYUE, HANSOH PHARMA'S DRUG FOR THE RARE DISEASE NMOSD, WAS COMPLETED IN CHINA

THE FIRST-LINE TREATMENT INDICATION OF AMEILE, CHINA'S FIRST ORIGINAL THIRD-GENERATION EGFR-TKI, WAS ADDED TO THE NATIONAL?REIMBURSEMENT?DRUG LIST

HANSOH PHARMA'S SEVERAL INNOVATIVE DRUGS AND NEW INDICATIONS WERE ADDED TO THE 2022 NATIONAL?REIMBURSEMENT?DRUG LIST

EQRX’S MARKETING AUTHORIZATION APPLICATION FOR AUMOLERTINIB IN EGFR-MUTATED NON-SMALL CELL LUNG CANCER ACCEPTED BY THE EUROPEAN MEDICINES AGENCY (EMA)

2022 ESMO ASIA | HANSOH PHARMA'S AMEILE FILLS DATA GAPS WITH EIGHT MORE INNOVATIONS